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Abstract
Cell migration and invasion are key processes in the metastasis of cancer, and suppression of these steps is a promising strategy for cancer
therapeutics. The aim of this study was to explore small molecules for treating colorectal cancer (CRC) and to investigate their anti-metastatic
mechanisms. In this study, six CRC cell lines were used. We showed that YH-306 significantly inhibited the migration and invasion of CRC cells
in a dose-dependent manner. In addition, YH-306 inhibited cell adhesion and protrusion formation of HCT116 and HT-29 CRC cells. Moreover,
YH-306 potently suppressed uninhibited proliferation in all six CRC cell lines tested and induced cell apoptosis in four cell lines. Furthermore,
YH-306 inhibited CRC colonization in vitro and suppressed CRC growth in a xenograft mouse model, as well as hepatic/pulmonary metastasis
in vivo. YH-306 suppressed the activation of focal adhesion kinase (FAK), c-Src, paxillin, and phosphatidylinositol 3-kinases (PI3K), Rac1 and
the expression of matrix metalloproteases (MMP) 2 and MMP9. Meanwhile, YH-306 also inhibited actin-related protein (Arp2/3) complex-medi-
ated actin polymerization. Taken together, YH-306 is a candidate drug in preventing growth and metastasis of CRC by modulating FAK signalling
pathway.
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Introduction
Although screening, surgical resection and adjuvant therapy have
improved the outcome for patients with colorectal cancer (CRC), CRC
is still the third-leading cause of cancer-related deaths [1]. More than
140,000 new cases of CRC were estimated and more than 50,000
individuals will die from CRC during 2013 in the United States [2]. To
address this conundrum, many studies focused on research for new
therapies to target metastatic progression, as metastasis from the pri-
mary site of tumour growth to distant organs was the leading cause
of cancer-related mortality [3].
Cancer metastasis involves a series of processes, including cell
adhesion, spreading, migration, invasion and colonization in the new
sites [4]. These processes are regulated by a variety of proteins,
including cellular adhesion molecules, chemokines and their recep-
tors, MMPs, other metastasis proteins and their downstream signal-
ling pathways [5]. The adhesion of cells onto specific extracellular
matrix (ECM) components induces the formation of focal adhesions,
followed by the recruitment of cytoplasmic proteins, such as focal
adhesion kinase (FAK), c-Src, cdc42, Rac, paxillin and talin [6].
Among these molecules, the FAK/Src complex mediates signalling by
binding to and phosphorylating downstream molecules. In response
to extracellular stimuli, autophosphorylation of FAK on Tyr397 regu-
lates focal adhesion disassembly through controlling the phosphory-
lation of paxillin on Tyr31 and Tyr118 [7]. Downstream of FAK
signalling, the p85 subunit of PI3K binds to FAK resulting in PI3K
phosphorylation, which leads to cell migration [8, 9]. The initiation of
cell adhesion and focal adhesions is also associated with the small
G-proteins Rho, cdc42 and Rac, which regulate actin cytoskeleton
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dynamics leading to the formation of cell protrusions [10]. During cell
migration, the actin-related protein 2/3 complex drives the polymeri-
zation of actin filaments to direct cell protrusion, influencing cell
migration and invasion [11].
To explore potential drug candidates against CRC metastasis, we
screened one type of novel aryl tetrahydro-b-carboline derivatives for
their inhibition efficacy towards CRC cell phenotypic assays, and
found that YH-306 showed a significant inhibitory effect on the pro-
gression and development of CRC. In vitro, YH-306 significantly inhib-
ited CRC cell migration, invasion, proliferation and colonization, and
induced CRC cell apoptosis. In vivo, YH-306 depressed CRC growth
and suppressed hepatic/pulmonary metastasis. Finally, we found that
YH-306 blocked the activation of FAK and FAK-related signalling path-
way, leading to the suppression of CRC growth and metastasis.
Materials and methods
Reagents, cell and animals
The antibodies used in this study were anti-Arp3; C-myc, Bax, Bcl-xl,
Cleaved Caspase3, FAK, Phos-FAK, Phos-PI3K, MMP2, MMP9, tissue
inhibitor of metalloproteinases 1 (TIMP1), Paxillin, Phos-paxillin, Erk,
Phos-Erk (Cell Signaling Technology), c-Src, Phos-c-Src (Santa Cruz
Biotechnology) and Rac1 (Millipore). DAPI was purchased from Sigma-
Aldrich. Phalloidin was provided by Invitrogen. All of the media were
obtained from Gibco. All CRC cell lines were obtained from the Ameri-
can Type Culture Collection (ATCC). Medium was supplemented with
10% FBS, penicillin (100 units/ml) and streptomycin (100 units/ml).
BALB/c mice and nude mice were from the National Rodent Laboratory
Animal Resources, Shanghai Branch of China. All animal experimental
protocols were approved by the Animal Investigation Committee of the
Institute of Biomedical Sciences, East China Normal University.
Chemical synthesis of compound YH-306
As previous report [12, 13], compound YH-306 (Fig. 1A) was synthe-
sized by our laboratory with greater than 98% purity. To a solution
of 4-hydroxyphenylacetic acid (152 mg, 1.0 mmol) in anhydrous
N,N-dimethylformamide (5.0 ml) was added 1-(3-dimethylaminopropyl)-
3-ethyl-carbodiimide hydrochloride (249 mg, 1.3 mmol) and 1-hydroxy-
benzotriazole (149 mg, 1.1 mmol) at 0°C, the reaction mixture was
stirred for 10–15 min., then 1,3,4,9-tetrahydro-b-carboline (172 mg,
1.0 mmol) was added. The mixture was stirred for another 3 hrs at
room temperature and diluted with H2O and extracted with ethyl acetate
(3 9 60 ml). The combined organic phase was dried over anhydrous
sodium sulphate, then concentrated in vacuo and the crude product
was chromatographed over silica gel to give 199 mg (65% yield) of
compound YH-306.
Migration and invasion assays
For CRC cells, the migration and invasion assay was performed as pre-
viously reported [14]. After overnight starvation, the cells were
scratched with a pipette tip followed by the addition of YH-306. Images
were taken after 16 hrs, and migrated cells were counted. The migration
and invasion of CRC cells was assessed by the modified Boyden’s
chamber assay in 24-well cell culture plate with 8-lm pore.
Cell adhesion and cell spreading assays
Adhesion and spreading assays were performed with some modifica-
tions [15]. The 96-well plates were incubated with 2.5 lg fibronectin
(Invitrogen) or 1 lg type I collagen. After treatment, tumour cells were
added to each well and allowed to attach for 1 hr. Non-adherent cells
were removed with PBS gently and adherent cells were stained with
crystal violet. Spreading cells were identified as those cells that had dis-
tinguishable cytoplasm.
Cell proliferation, live/dead and apoptosis assays
As previously reported [16], the effect of YH-306 on CRC cell proliferation
was determined by MTS assay. LIVE/DEAD Viability/Cytotoxicity kit (Invi-
trogen) was utilized to assess the cell death objectively by specified the
protocol. Apoptosis of CRC cells induced by YH-306 was measured by
annexin V-FITC/Propidium Iodide (PI, BD Biosciences) dual staining assay.
Colony formation assay
The ability of isolated single cells to form colonies was tested using
both two dimensional (2D) and 3D culture as described previously [17].
All cells were stained with crystal violet. Experiments were set up in
triplicate and medium was changed twice a week.
Immunofluorescence
Immunofluorescence assays were performed according to the method
previously described [18]. The YH-306-treated cells were incubated with
primary antibody overnight at 4°C, followed by incubation with second-
ary antibodies. A laser scanning confocal imaging system (Leica, Heidel-
berg, Germany) was used to observe stained cells.
Animal models for tumour growth and
metastasis
As previously reported [19], for tumour xenografts, 2 9 106 HT-29
cells were injected into nude mice subcutaneously and the mice were
treated consecutively for 20 days, with the measurement of bodyweight
and the tumour dimensions. For metastasis, BALB/c mice were used.
CT-26-luciferase (CT-26-luci) colon cancer cells were harvested and re-
suspended. Hepatic metastases were generated by intrasplenic injection
of 2.5 9 104 of cancer cells and splenectomy. Pulmonary metastases
were generated by tail vein injection of 2.5 9 104 of cancer cells. Mice
were killed after 2 weeks. All mice were intraperitoneally injected with
YH-306 (20 and 50 mg/kg) every day, with an equivalent volume of
dimethyl sulfoxide (DMSO) was injected in control animals (n = 5).
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Immunohistochemistry
Paraffin-embedded tissues were sectioned at 5 lm, haematoxylin and
eosin staining was performed according to a standard protocol. Images
were taken using a Leica microscope (DM4000B; Leica). The results
were analysed with Image-Pro Plus 6.0 software.
In vitro actin polymerization assay
This assay was performed as described [11] with some modifications.
In brief, purified pyrene-labelled actin was re-suspended and incubated
in general actin buffer for 1 hr on ice to depolyermize any actin oligo-
mers, followed by micro-centrifugation at 4°C for 30 min. Exactly,
2 lM of actin alone or 2 lM of actin, 13 nM of Arp2/3 complexes and
100 nM of WASP protein VCA domain were incubated with DMSO (con-
trol) or 50 lM YH-306 for 15 min. on ice before pyrene actin fluores-
cence was measured over time.
Western blot analysis
After the treatment of YH-306, cells were harvested and lysed in radio
immunoprecipitation assay buffer containing protease/phosphotase
inhibitors (Roche). Lysates were combined with sample loading buffer
and heated at 100°C for 10 min. Protein samples were eluted in sample
buffer and subjected to SDS-PAGE.
Measurement of YH-306 binding to Arp2/3 using
biolayer interferometry
Protein–small molecules interactions were examined with an Octet
QK (ForteBio, Shanghai, China) by biolayer interferometry as described
in previous studies [20–23]. In brief, Arp2/3 protein complex was
PEG-biotinylated with NHS-PEG4biotin (Thermo-Pierce), and buffer
exchanged on PD-10 desalting columns. Then, biotinylated Arp2/3 pro-
tein complex was immobilized on streptavidin-coated fibre optic tips
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Fig. 1 YH-306 suppresses the migration
and invasion of colorectal cancer cells. (A)
Chemical structure of YH-306 (molecular
weight 306). (B) Inhibitory effect of
YH-306 on wound healing migration of
HT-29, CT-26 and HCT116 cells. Left
panel, images of cell migration. Right
panel, quantitative data for the relative
percentage of migrated cells. (C) YH-306
suppressed transwell migration of CT-26
cells. (D) YH-306 inhibited the invasion of
CT-26 cells through type I collagen (Upper
panel) or Matrigel (Lower panel).
*P < 0.05; **P < 0.01; ***P < 0.001.
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(ForteBio). YH-306 or CK-636, the positive control, was diluted into
optimized binding buffer [25 mM Na HEPES (pH 8.0), 50 mM arginine-
glutamate, and 150 mM NaCl].
Statistical analysis
Results were statistically analysed using the Student’s t-test with Micro-
soft Excel, and all experiments were repeated at least three times. A
value of P < 0.05 was considered significant.
Results
YH-306 suppresses the migration and invasion of
CRC cells
Migration is a key step during tumour metastasis, which is the
critical reason for treatment failure and poor prognosis in
patients with CRC [24]. YH-306 was identified as a new inhibitor
of CRC cell migration via screening more than 70 analogues. As
shown in Figure 1B, YH-306 significantly inhibited the migration
of two human CRC cell lines (HCT116 and HT-29) and one
mouse CRC cell line (CT-26) in a wound healing migration assay.
To confirm the effect of YH-306 on migration, a transwell migra-
tion assay was performed and we found that migration of CT-26
cells was significantly reduced in a dose-dependent manner after
treatment of YH-306, as shown in Figure 1C. During metastasis,
cancer cells need to pass through the basement membrane, and
invade surrounding tissues to infiltrate distant organs [5]. To
assess the effect of YH-306 on this process, we used type I
collagen and Matrigel as substrates. As shown in Figure 1D,
YH-306 evidently prevented CT-26 cells from invading the type I
collagen- or Matrigel-coated membrane in a dose-dependent
manner.
YH-306 inhibits adhesion and spreading of CRC
cells
Cancer cell adhesion and cell spreading based on ECM compo-
nents such as type I collagen or fibronectin are required for
movement of metastatic cancer into new sites. Suppression of
adhesion and spreading of CRC cells is therefore considered as
a promising strategy for metastatic cancer therapy [15]. To
determine whether YH-306 inhibit CRC cell adhesion, we treated
HCT116 and HT-29 seeded onto type I collagen or fibronectin
with various concentrations of YH-306. As shown in Figure 2A,
50 lM YH-306 significantly reduced HCT116 and HT-29 adhesion
onto type I collagen or fibronectin. Quantitative data revealed that
50 lM YH-306 inhibited 67% of HCT116 cell and 78% of HT-29
cell attachment to type I collagen, and attachment to fibronectin
was also significantly reduced by YH-306. These results showed
that YH-306 significantly inhibited HCT116 and HT-29 cells
attachment to type I collagen or fibronectin in a dose-dependent
manner. Furthermore, we tested the effect of YH-306 on cell
spreading, and results in Figure 2B showed that YH-306 signifi-
cantly suppressed cell spreading on type I collagen or fibronectin
in a dose-dependent manner. Cells treated with YH-306 retained
a rounded morphology (Fig. 2B) and had defects in polarized
extension (Fig. 2C).
YH-306 inhibits CRC cell growth and induces
apoptosis
MTS assays were used to test the effect of YH-306 on the prolifera-
tion of CRC cells. As shown in Figure 3A, YH-306 inhibited the growth
of HCT8, HT-29, HCT116, SW480, SW620 and CT-26 cells in a dose-
dependent manner after 48 hrs treatment. Fluorescence-activated cell
sorting analyses in Figure 3B revealed that 50 lM YH-306 increased
apoptosis of HCT116, CT-26, HT-29 and SW620 cells by sevenfold,
5.2-fold, 3.6-fold and 3.4-fold respectively, compared with untreated
cells. The percentage of live (Calcein AM positive) HCT116 cells
decreased from 89.9% in control groups to 56.3% in 50 lM YH-306-
treated groups and that decreased to only 23.3% in 50 lM YH-306-
treated SW480 cells (Fig. 3C). In addition, the percentage of Calcein
AM-positive cells was reduced by YH-306 in a dose-dependent man-
ner. Overexpression of c-myc is associated with the progression of
CRC [25]. YH-306 inhibited the expression of c-myc and Bcl-xl
(Fig. 3D), which is highly expressed in CRC and is correlated with
prognosis of CRC [26]. In contrast, YH-306 induced the expression of
the pro-apoptotic protein Bax. These results suggested that YH-306
suppressed proliferation and induced apoptosis of CRC cells. Further-
more, to examine whether YH-306 also target other cancer cells, we
carried out MTS assay to test the effect of YH-306 on prostate cancer
cell LNCaP and breast cancer cell MDA-MB-231, and the results
shown in Figure S1 displayed that YH-306 also inhibited cell growth
of prostate cancer and breast cancer.
YH-306 suppresses colony formation and
xenograft tumour growth
The colony formation assay measures anchorage independent
growth, and is considered the most stringent assay for mimicking the
tumour growth in vivo. We first tested the effect of YH-306 on the 2D
colony formation of HCT116 cells. As shown in Figure 4A, the number
of colonies in experimental groups treated by YH-306 at 10, 20 and
50 lM only was 56.7%, 7.5% and 6.9%, respectively, of the number
of colonies formed by untreated groups. HT-29 cells generated
results analogous to that of HCT116 cells. In 3D colony formation
assays, YH-306 also inhibited colony formation of HCT116 cells sig-
nificantly compared with the untreated controls (Fig. 4B). Meanwhile,
the size of the colonies formed in YH-306-treated groups is much
smaller than that in untreated groups.
To test the effect of YH-306 on the growth of CRC in vivo, we per-
formed tumour xenograft assays. After administration of 20 and
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50 mg/kg/day YH-306 for 20 days, as shown in Figure 4C, the aver-
age tumour volumes were 544.54  32.15 mm3 (20 mg/kg/day) or
377.41  44.13 mm3 (50 mg/kg/day), whereas that of untreated
groups was 950.66  34.30 mm3. In addition, the average tumour
weight in untreated groups was 0.73  0.11 g, and that in 20 or
50 mg/kg/day YH-306 groups was 0.50  0.05 g or 0.34  0.05 g
respectively. However, the bodyweight of the mice treated with
YH-306 had no obvious changes (Fig. 4C). Furthermore, we noticed
that the expression of c-myc was reduced in YH-306-treated groups
(Fig. 4D). In contrast, cleaved caspase3 expression was up-regulated
in YH-306-treated groups (Fig. 4D). All together, the above results
implied that YH-306 suppressed primary tumour growth through inhi-
bition of proliferation and induction of apoptosis.
YH-306 reduces hepatic metastasis of CRC
Metastasis to distant organs is an ominous characteristic of cancer,
and 80% of CRC patients with recurrent diseases develop hepatic
metastasis [5]. To examine YH-306 as a potential agent against hepa-
tic metastasis, CT-26 cancer cells exogenously expressing luciferase
(CT-26-luci) were injected into the spleen and mice were treated by
A
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Fig. 2 YH-306 inhibits cell adhesion and
spreading of colorectal cancer cells. (A)
Upper panel, representative images of cell
adhesion. HT-29 or HCT116 cells were
seeded onto type I collagen or fibronectin
coated 96-well plates. Lower panel, results
of cell adhesion are shown in the bar
graph. (B) Upper panel, representative
images of cell spreading. Lower panel,
plot shows the per cent of cells that are
spread for each treatment condition. (C)
Time-lapse micrographs of representative
cells exposed to 50 lM YH-306 or vehicle
control. *P < 0.05; **P < 0.01;
***P < 0.001.
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two different dosages of YH-306 (20 and 50 mg/kg) or vehicle control
every day. After treatment for 14 days, as shown in Figure 5A, biolu-
minescence graphs showed that CT-26-luci cells largely localized in
the abdomen region in untreated mice, and treatment of 50 mg/kg/
day YH-306 significantly suppressed the metastasis with photon flux
reduced by 77.02%. Then the mice were killed, and we found that
tumour was not only localized in the liver but also spread to the intes-
tines mesentery. To confirm the effect of YH-306 on hepatic metasta-
sis, the liver was taken out and bioluminescence was examined. As
shown in Figure 5B, 50 mg/kg/day YH-306 treatment significantly
suppressed hepatic metastasis with photon flux reduced by 67.60%.
Furthermore, we counted the tumour nodules per liver, compared
with the untreated group, and found that the number of tumour
nodules in livers from mice treated by 20 and 50 mg/kg/day YH-306
was reduced by 14.39% and 65.31%, respectively (Fig. 5C). Mean-
while, there was no obvious change in weight, or disruption in kidney
or lung morphology in YH-306-treated mice (Fig. 5D). These results
suggested that YH306 inhibited hepatic metastasis of CRC in vivo
with no significant side effects.
YH-306 reduces pulmonary metastasis of CRC
To evaluate the effect of YH-306 on pulmonary metastasis, which is
one cause of fatality in patients with CRC [27], we used the pulmo-
nary metastasis model based on tail vein injection. As shown in
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Fig. 3 YH-306 inhibits colorectal cancer
cell growth and induces apoptosis. (A)
Effect of YH-306 on the proliferation of
colorectal cancer cells was determined by
MTS assay. The percentages of proliferat-
ing cells were relative to cells exposed to
0.1% DMSO. (B) Flow cytometry analysis
was used to measure apoptosis of CT-26,
HT-29, SW620 and HCT16 cells treated
with YH-306 for 36 hrs. Cells positive for
both propidium iodide (PI) and Annexin V
were considered apoptotic. (C) Inhibitory
effect of YH-306 on HCT116 and SW480
cells detected by Live&Dead assays. Left
panel, representative graphs of SW480
cells were taken after treatment of 36 hrs.
Right panel, quantification of the percent-
ages of Calcein AM-positive cells. (D) Pro-
tein expression of c-myc, Bax and Bcl-xl
in HT-29 cells treated by YH-306 or vehi-
cle control. *P < 0.05; **P < 0.01;
***P < 0.001.
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Figure 6A and Figure 6B, after treatment for 14 days, 20 mg/kg/day
YH-306 showed no significant inhibitory effect on pulmonary metas-
tases of CT-26-luci cells, 50 mg/kg/day YH-306 obviously inhibited
pulmonary metastasis by 78.93%, compared with untreated controls.
To confirm this result, the lungs were dissected from mice treated
with YH-306 or vehicle control. YH-306 suppressed the number of
tumour nodules in lung with significance (Fig. 6C and D). We noticed
that the liver is also a metastatic target organ after tail vein injection.
As shown in Figure 6E, colorectal tumour cells colonized the liver in
60% of untreated mice, whereas liver metastasis frequency was
reduced to 40% and 20% respectively after administration of 20 and
50 mg/kg/day YH-306. These results indicated that YH-306 inhibited
lung metastasis.
YH-306 suppresses the activation of proteins in
the FAK pathway
Focal adhesion formation plays an important role in cell motility [28].
To understand the mechanisms involved in the suppressive effect of
YH-306 on cell motility, we detected the effect of YH-306 on the dis-
tribution of F-actin and paxillin which are major components of focal
A
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Fig. 4 YH-306 suppresses colonization of
colorectal cancer cell and inhibits xeno-
graft colorectal cancer growth. (A) Sup-
pression of 2D colony formation by
various concentrations of YH-306 for
14 days. Images show representative
cases at 14th day. Bar graph shows the
relative number of HCT116 and HT-29 col-
onies. (B) In colonization assay, YH-306
inhibited the colony formation of HCT116
cells. The average colony formation from
three independent experiments was
shown. (C) After the injection of cancer
cells, tumour volume and bodyweight
were measured every 2 days. At the 20th
day, the tumours were excised and
tumour weight was recorded. (D) Immu-
nohistochemistry analysis of cleaved cas-
pase3 and c-myc expression in tumours
from nude mice treated with DMSO or
YH-306. Black arrows indicate the cells
stained with specific antibody (upper
panel). Quantitative data based on at least
five independent sections from mice.
*P < 0.05; **P < 0.01; ***P < 0.001.
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adhesion. As shown in Figure 7A upper panel, F-actin and paxillin
were mainly localized in extended cell protrusions initially contacting
with ECM. In contrast, after YH-306 treatment, cells retained a round
morphology without the formation of protrusions and paxillin were
distributed dispersedly, which is consistent with the results above
(Fig. 2C). FAK is a critical mediator in regulating cell motility including
cell adhesion, spreading, migration and invasion, we found that the
phosphorylation of FAK and paxillin was significantly reduced by
YH-306 for 60 min. in cells exposed to fibronectin (Fig. 7A).
To further clarify the mechanism that underlies the inhibitory
effect of YH-306 on CRC cells, we measured activation of several pro-
teins involved in FAK pathway using Western blot. As shown in
Figure 7C and D, after HT-29 and CT-26 cells were exposed to 50 lM
YH-306 for 24 hrs, YH-306 significantly reduced the phosphorylation
of FAK at Tyr397. We also performed experiments to determine
whether YH-306 could act a direct inhibitor of FAK kinase activity
in vitro, and found that YH-306 did not show significant inhibitory
effect on FAK kinase activity in vitro compared to staurosporine as
shown in Figure S2A and B. In HT-29 cells, as shown in Figure 7C,
the phosphorylation of proteins involved in the FAK pathway, includ-
ing c-Src, paxillin and PI3K, was significantly reduced by 50 lM
YH-306. The decreased phosphorylation of PI3K was also found in
CT-26 cells treated by 50 lM YH-306 (Fig. 7D). Activation of Rac1 is
a vital component in FAK pathway regulating cell motility [29], and
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Fig. 5 YH-306 reduces hepatic metastasis
of colorectal cancer. (A) CT-26-luci cells
were injected into the spleen of BALB/c
mice. Representative images were taken
at the 7th, 10th and 14th day respectively
(left panel). Quantification of metastatic
cells in whole body was determined by
bioluminescence analysis (right panel). (B)
Colorectal cancer cell metastases in liver
and quantitative data of metastatic cells
only in liver. (C) Upper panel, observa-
tional analyses of colorectal cancer metas-
tases in livers from mice treated by YH-
306 or DMSO. Lower panel, the cancer
metastatic nodules on the liver surface
were counted from mice. (D) The body-
weight of mice was measured. The kidney
and lungs were excised from indicated
mice, then fixed in 4% paraformaldehyde
and stained with haematoxylin and eosin.
*P < 0.05; **P < 0.01; ***P < 0.001.
390 ª 2015 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
pull down assays revealed that YH-306 inhibited the activation of
Rac1 GTPase in HT-29 cells (Fig. 7E). To examine the individual
importance of Src, PI3K and Rac1 for survival, adhesion and migra-
tion of CRC cell, we used Src inhibitor PP1, PI3K inhibitor LY294002
and Rac1 inhibitor NSC23766. The data shown in Figure S3 sug-
gested that YH-306 suppressed cell growth, adhesion and migration
of CRC cell through Src, PI3K and Rac1, but not depending on them.
It is reported that MMPs play an important role in the cancer met-
astatic cascade [30], and the expression of MMP2 and MMP9 is
induced by FAK [31]. In this study, we found that 50 lM YH-306
strongly reduced MMP2 and MMP9 expression in HT-29 cells. To
confirm this effect of YH-306, we then measured the expression of
TIMP1 and found that YH-306 up-regulated the expression of TIMP1
in a dose-dependent manner (Fig. 7C). Meanwhile, in CT-26 cells,
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Fig. 6 YH-306 reduces pulmonary metas-
tasis of colorectal cancer. (A) After the
administration of YH-306, representative
images were taken at the 14th day (left
panel) and quantification of metastatic
cells in mice body was performed with
bioluminescence analysis (right panel). (B)
Mice were anaesthetized and lungs were
removed from mice. Images show the
metastases in lungs. (C) Left panel, obser-
vational analyses of colorectal cancer
metastasis in lungs from mice treated
with YH-306 or DMSO. Right panel, lungs
from indicated mice were stained with
haematoxylin and eosin. (D) The cancer
metastasis nodules of lung surface from
mice were counted. (E) The percentage of
tail vein-injected mice with liver metasta-
ses in the colorectal cancer cell lung
metastasis model. *P < 0.05; **P < 0.01;
***P < 0.001.
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50 lM YH-306 also showed significantly inhibitory effect on the
expression of MMP2 and MMP9 as well as the phosphorylation of Erk
(Fig. 7D).
YH-306 suppresses the distribution of Arp3 and
inhibits Arp2/3 complex-mediated actin
polymerization
The Arp2/3 complex drives many types of cell movement such as
protrusion formation, cell spreading and actin polymerization [11,
32]. To examine the effect of YH-306 on the Arp2/3 complex, we
examined the recruitment of Arp3. The recruitment of Arp3 to the
protrusions of cells treated with YH-306 was reduced compared with
untreated cells (Fig. 7B). The cell morphology in Figure 7A and B
showed some defects in the cytoskeleton of cells treated with YH-
306. In HT-29 and CT-26 cells, the expression of Arp3 did not show
a significant change (Fig. 7C and D), suggesting that YH306 inhibited
the recruitment but not the expression of Arp3. To confirm whether
this morphology result from the inhibition of Arp2/3 complex-regu-
lated actin polymerization which is required for dynamic morphologi-
cal changes [33], we performed Arp2/3 complex-regulated actin
polymerization assays in vitro. As shown in Figure 7B lower panel,
YH-306 inhibited Arp2/3 complex-regulated actin polymerization at
10 min. [11]. To further determine whether YH-306 could acts an
ATP analogue and disturb ATP-dependent actin polymerization on its
own, we perform ATP-dependent actin polymerization assay in which
Arp2/3 complex and N-Wasp protein were not included. The result
A
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Fig. 7 YH-306 suppresses FAK pathway
and disrupts the recruitment of Arp3. (A)
Focal adhesion formation in HT-29 cells
treated with 0.1% DMSO or 50 lM
YH-306 (upper panels). Phosphorylation
of FAK and paxillin in HT-29 cells exposed
to fibronectin and treated with YH-306 for
1 hr (lower panel). (B) Immunofluores-
cence of Arp3 in DMSO- or YH-306-trea-
ted HT-29 cells (upper panels) and time
course of actin polymerization in the pres-
ence of 50 lM YH-306 (lower graph).
(C and D) Colorectal cancer HT-29 (C) or
CT-26 cells (D) were treated with YH-306,
and whole-cell lysates were subjected to
immunoblotting with antibodies against
Arp3, Paxillin, PI3K, FAK, MMP9, MMP2,
TIMP1 and Erk. (E) The activation of Rac1
was detected by pull down assays in
HT-29 cells.
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was shown in Figure S2C, suggesting that YH-306 did not show
significant inhibitory effect on ATP-dependent actin polymerization
at 10 min.
Discussion
In this study, we demonstrated that a novel synthetic small molecule,
YH-306, inhibited colorectal tumour growth and hepatic/pulmonary
metastasis. The inhibitory effect of YH-306 resulted from the sup-
pression of proliferation and motility. The potential mechanism by
which YH-306 affected CRC may be because of inhibition of FAK and
Arp2/3 pathway.
Liver and/or lungs are the typical sites of CRC metastases and
hepatic/pulmonary metastasis account for the lethality in patients
with CRC [5, 27, 34]. So, effective anti-metastasis drugs for malig-
nant CRC treatment are urgently needed. YH-306 prevented CRC
cells from invading the liver after intrasplenic injection. Besides in
the liver, colorectal tumours were also observed in the intestines
mesentery (data not shown). Our data suggested that YH-306 also
inhibited the localization of CRC to the intestines mesentery. Com-
pared with the liver, the lungs are the second most frequently target
organ of CRC [5]. YH-306 inhibited lung metastasis of CRC cells,
and suppressed the liver metastasis caused by tail vein injection of
CRC cells (Figs 5 and 6). In addition to the inhibition of CRC metas-
tasis, YH-306 also inhibited colorectal tumour growth by inhibiting
CRC proliferation and inducing cell apoptosis (Figs 3 and 4). These
results suggested that YH-306 inhibited the progression of CRC in
vivo.
Migration is necessary for malignant cancer cells to invade adja-
cent tissues and metastasize to distant organs [35], and suppressing
the initiation of migration is a promising approach to inhibit cancer
cell dissemination [36]. The process of migration underlies the inva-
sion of cancer cells, and intravital microscopy studies displayed that
cancer cells switch invasion strategies in response to ECM resulting
in intravasation into blood vessels [37]. YH-306 showed a signifi-
cantly inhibitory effect on the migration and invasion of CRC cells in a
dose-dependent manner (Fig. 1). We also found that YH-306 was
more effective at inhibiting migration and invasion than proliferation
in CRC cells under the same concentrations and time (data not
shown).
The process by which cancer cells attach to the vessel wall in
distant organs and migrate out of the vessel is considered another
crucial step of cancer metastasis [38]. During this process, to
interact with neighbouring cells and ECM, cell–cell and cell–ECM
adhesions are formed [39], and cell protrusion and polarity is also
important for invasive tumours [6, 40]. After YH-306 treatment,
CRC cells HCT116 and HT-29 were prevented from attachment,
and remained rounded without polarity as well as failed to form
protrusions at the leading edge in response to type I collagen or
fibronection stimuli (Fig. 2). Consistent with these results, YH-306
treatment resulted in the reduction in filament-based cell–ECM
contacts localized at cell adhesions and a random distribution of
paxillin at the peripheral sites (Fig. 7A, upper panel). These data
implied that YH-306 inhibited migration and invasion resulting
from interfering with initial processes in the metastatic cascade,
which leads to the suppression of metastasis.
Cell migration is a highly integrated multistage process that
is initiated by the protrusion of the cell membrane and focal
adhesions [41, 42]. FAK and Arp2/3 are important factors during
cell migration. FAK is correlated with the prognosis and clinico-
pathological parameters of some human malignancies, including
CRC [43, 44]. Arp2/3 controls network of actin filaments and
drives membrane protrusion during migration. Importantly, FAK
and Arp2/3 complex associate and colocalize at transient struc-
tures formed early after adhesion during the cell migration [11].
On the other hand, FAK/PI3K/Rac1 signalling also plays an
important role in several kinds of cancer including breast cancer
and CRC [45, 46]. Localization of FAK into adhesions induces its
phosphorylation at Tyr397 and subsequently phosphorylation of
c-Src and paxillin which also play an important role in focal
adhesions [10, 47, 48]. Phosphorylated PI3K induces the activa-
tion of Rac1 [49]. Rac1 activity induces the recruitment of Arp2/
3 complexes [42], which is considered as a potential risk factor
for liver metastasis of CRC [50, 51]. FAK also induces the
expression of MMP2 and MMP9 accounting for cancer invasion
and metastasis via ERK or JNK pathways [31, 52, 53]. The effect
of YH-306 on the ERK phosphorylation was weak, implying that
YH-306 inhibited MMP2 and MMP9 expression via JNK pathway
probably. In this study, YH-306 inhibited FAK/PI3K/Rac1 pathway
activation and the recruitment of Arp3 as well as the expression
of MMP2 and MMP9, resulting in the suppression of CRC
metastasis. In addition, as shown in Figure 7B, YH-306 sup-
pressed the Arp2/3 complex-mediated actin polymerization which
plays an important role in cell migration and invasion. Unlike the
small molecule, CK636, used as a positive control compound,
directly bound to Arp2/3 to block movement of Arp2 and Arp3
into their active conformation in the polymerization of actin (data
not shown), which was consistent with previous reports [32, 54].
YH-306 did not bind to the Arp2/3 complex directly (data not
shown), suggesting that YH-306 inhibited Arp2/3 complex-regu-
lated actin polymerization via other means.
Collectively, in this study, we provided evidence that YH-306
inhibited CRC cell migration, invasion and proliferation in vitro result-
ing in the suppression of growth and metastasis in vivo via inhibition
of the FAK pathways, implying that YH-306 might be valuable in pre-
venting CRC growth and metastasis.
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